Relapse remains a major cause of treatment failure after autotransplantation (auto-PBSCT) for Hodgkin's disease (HD). The administration of non-crossresistant therapies during the post-transplant period may delay or prevent relapse. We prospectively studied the role of consolidation chemotherapy (CC) after auto-PBSCT in 37 patients with relapsed or refractory HD. Patients received high-dose gemcitabine-BCNU-melphalan and auto-PBSCT followed by involved-field radiation and up to four cycles of the DCEP-G regimen, which consisted of dexamethasone, cyclophosphamide, etoposide, cisplatin, gemcitabine given at 3 and 9 months post transplant alternating with a second regimen (DPP) of dexamethasone, cisplatin, paclitaxel at 6 and 12 months post transplant. The probabilities of event-free survival (EFS) and overall survival (OS) at 2.5 years were 59% (95% CI ¼ 42-76%) and 86% (95% CI ¼ 71-99%), respectively. In all, 17 patients received 54 courses of CC and 15 were surviving event free (2.5 years, EFS ¼ 87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study. PBSCT; auto-PBSCT; high-dose therapy; consolidation chemotherapy; gemcitabine High-dose therapy followed by autologous stem cell rescue has improved the long-term event-free (EFS) and overall survival (OS) for patients with relapsed or refractory Hodgkin's disease (HD). The probability of 5-year progression-free survival (PFS) for patients with HD autografted in first relapse ranged from 37 to 63% in selected series, while the PFS for patients autografted for primary refractory disease ranged from 15 to 50%. From these studies, predictors of better outcome after autotransplantation varied, but included 'minimal' disease status, chemosensitivity, normal LDH levels, good performance status, transplant in first relapse, absence of B symptoms at diagnosis, and administration of involvedfield radiotherapy post transplantation. In addition, factors identified by the International Prognostic Factors Project on advanced HD including low serum albumin, anemia, advanced age, and lymphocytopenia were associated with inferior EFS and OS rates after autotransplantation as well.
PBSCT; auto-PBSCT; high-dose therapy; consolidation chemotherapy; gemcitabine High-dose therapy followed by autologous stem cell rescue has improved the long-term event-free (EFS) and overall survival (OS) for patients with relapsed or refractory Hodgkin's disease (HD). The probability of 5-year progression-free survival (PFS) for patients with HD autografted in first relapse ranged from 37 to 63% in selected series, while the PFS for patients autografted for primary refractory disease ranged from 15 to 50%. From these studies, predictors of better outcome after autotransplantation varied, but included 'minimal' disease status, chemosensitivity, normal LDH levels, good performance status, transplant in first relapse, absence of B symptoms at diagnosis, and administration of involvedfield radiotherapy post transplantation. In addition, factors identified by the International Prognostic Factors Project on advanced HD including low serum albumin, anemia, advanced age, and lymphocytopenia were associated with inferior EFS and OS rates after autotransplantation as well. 23 The chief cause of treatment failure after autotransplantation is relapse or progression of disease, which occurs in about 50% of transplanted patients. The majority of relapses occur in sites of prior disease but new and unusual sites of recurrence have been described including the leptomeninges. 11 To prevent or delay disease relapse after auto-PBSCT, a clinical protocol was developed that contained the following novel features: (1) the standard BEAM (BCNU-etoposide-cytarabine-melphalan) conditioning regimen was modified to include gemcitabine because of its single-agent activity in relapsed/refractory HD; 24 (2) dose-intensive cyclophosphamide and etoposide were used for pre-transplant cytoreduction and stem cell mobilization; (3) involved-field radiation (IFRT) was administered post transplant to sites of bulky disease (42 cm) that were present just prior to transplantation; (4) consolidation chemotherapy was administered using two non-crossresistant chemotherapy regimens: DCEP-G (dexamethasone-cyclophosphamide-etoposide-cisplatin-gemcitabine) at 3 and 9 months post transplant alternating with DPP (dexamethasone-cisplatin-paclitaxel) at 6 and 12 months post transplant. The DCEP-G regimen was modified from DCEP, which was originally used for the treatment of post-transplant relapses of myeloma and later for cytoreduction and stem cell mobilization (Munshi NC, et al. Blood 1996; 88: 586a (abstract) 25 ). To permit inclusion of gemcitabine, a novel agent with significant activity against advanced HD both as a single agent and in combination with cisplatin, 24, 26 the doses of infusional cyclophosphamide, etoposide, and cisplatin were attenuated from the original DCEP. The rationale for including paclitaxel was three-fold: tubulin-active agents do not require wild-type p53, which is often mutated in advanced hematologic malignancies; 27 paclitaxel induces bcl-2 phosphorylation, which inactivates its antiapoptotic function; 28 and paclitaxel has modest but definite single-agent activity in advanced HD. 29, 30 We previously reported preliminary results of autotransplantation followed by consolidation chemotherapy (CC) for 33 NHL patients and 21 patients with HD. 31 In this paper, we describe and update the results of a complete cohort of 37 HD patients who were treated with this strategy. These results suggest that post-transplant CC is well tolerated and the total therapy was associated with favorable EFS and OS rates when compared to other published studies.
Materials and methods

Patients
A total of 37 patients with relapsed or refractory HD were enrolled between 8/98 and 8/03. The characteristics of these patients are shown in Table 1 . In all, 25 patients were considered to have relapsed disease since they demonstrated progression after obtaining a complete clinical response from initial therapy. Of 12 patients with primary refractory disease, seven were partial responders (PRs), but had radiographic (including abnormal gallium or PET scans) and/or histopathologic evidence of residual disease upon completion of induction therapy, while five patients had primary induction failure (PIF) based on lack of response or progression during or immediately after initial therapy.
Pre-transplant cytoreduction and mobilization chemotherapy consisted mainly of cyclophosphamide 4.5 g/m 2 over 12 h with Mesna for urothelial protection followed by etoposide 2.0 g/m 2 over 4-6 h. Hematopoietic growth factor support utilized G-CSF at a dose of 10 mg/kg. A measure of 30 l apheresis procedures were performed through indwelling catheters to collect a minimum of 4 Â 10 6 CD34 þ progenitors/kg body weight. The higher minimal collection standard was selected based on the protocol requirement to retain a backup stem cell product for infusion in the event of delayed marrow recovery after CC. After completion of mobilization therapy, patients were restaged and defined to have 'minimal' disease if all disease foci were p2 cm in maximal diameter and extranodal involvement was limited to one location; otherwise, the patients were defined to have 'bulky' disease. All patients gave written informed consent for participation in this IRB-approved protocol. CD34 þ progenitors/kg body weight were available as a backup infusion in the event of delayed marrow recovery after CC. Indeed, 35 of the 37 patients had at least 2 Â 10 6 CD34 progenitors/kg body weight available. G-CSF (300 or 480 mg based on body weight) was started on day þ 4 after autologous stem cell infusion. Standard antimicrobial prophylaxis was employed.
Involved-field external beam radiotherapy using megavoltage X-rays was administered post transplant to patients who entered transplant with bulky lymphadenopathy. Bulky disease was defined as any tumor mass that exceeded 2 cm in maximal diameter. As shown in Figure 1 , IFRT was scheduled to be given between weeks 5 and 8 post transplant. Patients who were in complete remission after transplant were scheduled to receive 20 Gy in 10 fractions of 2 Gy each over a 2-week period to bulky sites of disease that were present on entry to transplant. Patients with residual tumor masses post transplant were scheduled to receive 30 Gy in 15 fractions of 2 Gy each over a 3-week period. An external beam radiation boost of 6-10 Gy was given to residual tumor based on normal tissue tolerance.
Consolidation chemotherapy
At 3 and 9 months post transplant, patients with a neutrophil count X1500/ml, a platelet count X100 000/ml, and a serum creatinine p2 mg/dl were eligible to receive DCEP-G. The drug schedule for DCEP-G is shown in Figure 1 . If the neutrophil count was 1000-1500/ml or if the platelet count was 50 000-100 000/ml, then DCEP was given without the gemcitabine. If the platelet count was o50 000/ ml, or if the neutrophil count was o1000/ml, then the CC was not given. At 6 and 12 months post transplant, the patients were eligible to receive DPP. The drug schedule for DPP is also shown in Figure 1 . Post-treatment supportive care included G-CSF and antimicrobial prophylaxis. Backup CD34 þ progenitor cells were available for infusion following CC for delayed neutrophil counts (o100/ml at 14 days or o500/ml at 21 days) or if a life-threatening infection developed. The use of a backup stem cell product precluded further CC.
Statistical methods
For the EFS, an 'event' was defined to be either relapse or death from any cause. The EFS time was measured from the date of transplant to the 'event'. The OS was measured from the date of transplant to death from any cause. All patients were included in the survival analyses whether or not they received all of the intended treatments. The survival curves and survival rates were generated according to the Kaplan-Meier product-limit method and comparisons of survival curves were performed using the log-rank test. 32 In the multivariate analysis of prognostic factors, the Cox's proportional-hazard model was employed using a stepwise selection technique to determine variables related to EFS. 33 Figure 1 depicts the study treatment plan and Figure 2 is a flow diagram, which shows the actual treatment given. As shown in Figure 3 , for the entire cohort (n ¼ 37), the probability of EFS at 2.5 years was 59.1% (42.3-75.8%, 95% CI). The median EFS time has not yet been reached. There were 14 events (relapses or deaths) out of the 37 patients, meaning that 23 patients were surviving event free at last follow-up. The 14 events that constituted treatment failures are shown in Table 2 . These included two cases (5%) of treatment-related mortality and 12 episodes of relapse. It should be noted that of the 12 patients who relapsed, three have died and nine remain alive, undergoing further therapy at the time of analysis. Three patients who relapsed received second transplants including one patient who is in complete remission at almost 3.5 years after a syngeneic transplant with a TBI-based conditioning regimen and one patient who is in complete remission at 2.0 years after a second autologous transplant with a TBIbased conditioning regimen; a third patient has active HD after receiving an allogeneic transplant. 
Results
Treatment and survival
Effect of post-transplant radiotherapy
In all, 14 patients received post-transplant involved-field radiotherapy at a median of 2.75. months post transplant (range 1-4 months). Of the 14 patients, 13 patients were given radiotherapy as consolidation and nine showed objective radiographic responses in the treatment fields, while one patient (9812-11) was treated for early posttransplant progression in the mediastinum and responded but later relapsed in the abdomen. An additional 10 patients were scheduled to receive consolidative radiotherapy, but could not be treated due to early events (n ¼ 4), compromised pulmonary function (n ¼ 2), prior radiotherapy of the involved field (n ¼ 1), or patient refusal (n ¼ 3). Radiotherapy was well tolerated by 13 patients; one patient who had primary refractory disease and an 8 cm mediastinal mass both pre-and post transplant developed symptoms of restrictive lung disease about 1 month after post-transplant mediastinal radiation. At last follow-up, this patient had stable exertional dyspnea and a Karnofsky performance score of 90%. At last update, 10 of the 14 patients (71%) treated with involved-field radiotherapy were surviving continuously event free.
Consolidation chemotherapy
A total of 17 patients received a total of 54 courses of CC. Of these, 13 patients received three or four courses of therapy, while four patients have received one or two courses. A total of 20 patients did not receive any courses of CC due to early treatment failure (n ¼ 8), patient refusal (n ¼ 9), insufficient hematopoietic recovery (n ¼ 2), and severe respiratory dysfunction (n ¼ 1). Table 3 shows the number of patients who were scheduled and eligible to receive each phase of treatment and the number who were actually treated. It is apparent from this table that lack of compliance was a major reason that patients did not receive planned treatments. In addition, about 20% of patients who were scheduled to receive CC could not do so because of the concurrent medical conditions, which are listed. As shown in Figure 4 , grade 3 or 4 hematologic toxicities occurred in the majority of patients (B80%) after administration of DCEP-G, but in only a minority of patients after DPP (B25%). No patients required an infusion of backup stem cells for delayed marrow recovery, although one patient received only one consolidation treatment due to insufficient platelet recovery at the 6-month time point. One case of secondary myelodysplasia (RAEB) developed 5.5 years after transplant in a patient who had extensive pre-transplant therapy including MOPP and radiation therapy. Of the 17 patients, 15 who received at least one course of CC were surviving continuously event free at a median follow-up of 2.5 years. The probability of EFS at 2.5 years for these 17 patients was 87%, while the 2.5 year EFS for the 20 patients who did not receive any CC was 33% (p ¼ 0.001). In order to examine more directly what impact Table 2 Causes of treatment failure (3) pulmonary (1) Low blood counts (4) pulmonary (1) Low blood counts (3) pulmonary (1) Low blood counts (2) pulmonary (1) Liver steatosis (1) giant cell tumor (1) the CC treatments may have had on disease responses, we focused on the 10 patients with 'bulky' disease just prior to transplant therapy who received at least one course of CC. Of these 10 patients, eight were surviving event free at a median of 3.6 years of follow-up (range 0.4-5.2 years), while two patients had progression of Hodgkin's lymphoma at 1.5 months and 1.0 year post transplant. In addition, three of the eight patients who were surviving event free had modest but objective interval radiographic responses based on CT scans obtained just prior to the first consolidation treatment (about 3 months post transplant) and CT scans obtained after completion of the last consolidation treatment. Responses of index nodes in these patients were 2.5-1.8 cm (patient 9812-3), 2.4-1.5 cm (patient 9812-12), and 2.0-1.5 cm (patient 9812-27).
Prognostic factors
Among the 25 patients who were transplanted for relapsed disease, 16 were surviving event free at last update (projected median EFS not reached). In the group of 12 primary refractory patients who had never obtained a sustained remission, there were seven patients who had partial responses and five patients who had progressive disease during or within 1 month of completing initial chemotherapy. Among the seven PRs, there were four patients who remained event free at 4.0, 3.7, 3.4, and 1.8 years of follow-up, while among the five patients who exhibited PIF, three were surviving event free at 4.5, 2.3, and 0.4 years of follow-up.
A multivariate analysis of the EFS data was performed using the following covariates: gender, age (p35 vs 435), stage at enrollment (1 þ 2 vs 3 þ 4) , B symptoms at enrollment, bulky disease at enrollment (X5 cm vs smaller), marrow involvement at enrollment, truly primary refractory disease (yes vs no), post-transplant radiotherapy, and post-transplant CC. The results from the Cox's regression model using stepwise selection revealed that use of CC and post-transplant involved-field radiotherapy were significantly associated with better EFS, while the presence of B symptoms at study enrollment was negatively associated with EFS. The results of this analysis are summarized in Table 4 .
Discussion
In an effort to reduce the risk of relapse after autotransplantation for advanced HD, we developed a new conditioning regimen (gemcitabine-BCNU-melphalan) and introduced a series of post-transplant CC treatments. In this study, several observations were made. First, posttransplant CC using DCEP-G alternating with DPP was both feasible and well tolerated. Although moderate to severe myelosuppression occurred in the majority of patients after DCEP-G and to a lesser degree after DPP, no patients required backup stem cells and there were no additional cases of treatment-related mortality. Thus, although backup autologous stem cells may be useful for second autologous transplants (eg patient 9812-28), they do not appear to be required for patients who receive the alternating consolidation treatments, which were employed in this study. In addition, while longer followup is needed, only one case of secondary MDS/AML has been documented among the study patients, suggesting that CC did not significantly increase the short-term risk for this event.
Second, the study patients had encouraging 2.5 year projected EFS and OS rates of 59 and 86%, respectively. While it is difficult to isolate the relative contributions of the modified conditioning regimen and the CC to the favorable outcome observed, the EFS appeared to be high among the patients who received CC, with 87% of the treated patients projected to remain event free at 2.5 years. Indeed, use of CC was the most significant predictor of improved EFS on multivariate analysis, although such results must be interpreted cautiously when analyzing small data sets. In addition, a closer analysis of the impact of CC on the outcomes of the 10 patients with 'bulky' disease who also received this treatment revealed that eight of the 10 were surviving event free and several patients had objective radiographic responses of enlarged lymph nodes during the course of CC. However, we cannot exclude the possibility that these delayed responses would have occurred without additional therapy. Perhaps, the serial application of newer imaging modalities such as PET-CT scans with increased sensitivity and specificity for minimal residual disease may help to clarify the incremental contributions of post-transplant treatments in future studies. It should also be noted that the EFS curve for the study cohort appeared to form a plateau after 1 year of follow-up, suggesting that the CC may have delayed or prevented disease progression among the subgroup of patients with residual but more indolent disease. This subgroup of patients would be expected to exhibit a more delayed pattern of relapse. The approach taken in this study had at least two major limitations. The first limitation was that only about half of the intended recipients actually received CC due to early events, patient refusal, or the development of other conditions (eg thrombocytopenia), which precluded further chemotherapy. Certainly, this selection process may have amplified the favorable outcome, which was associated with the group of patients who survived event free long enough to receive CC. Our inability to provide the intended treatment to a substantial proportion of patients also highlights the difficulty of administering post-transplant therapies that entail hospitalizations and additional risks for morbidity and mortality. However, as the proportion of eligible patients who actually received CC remained fairly constant throughout the series of treatments, patient tolerance for successive courses of therapy did not appear to diminish significantly over time. An additional concern was whether administration of involvedfield radiotherapy might prevent patients from subsequently receiving CC. However, as shown in Figure 2 , six patients (46%) of the 13 who received involved-field XRT went on to receive CC, while 11 of 22 patients (50%) who did not have XRT received CC, arguing against the notion that patients could not tolerate both post-transplant modalities.
A second limitation was that post-transplant consolidation appeared to have little impact on those patients who relapsed early after transplant. B symptoms prior to transplant therapy was a significant predictor of treatment failure and may help to identify those patients who are at higher risk for early relapse. The mechanisms of treatment failure in these 'early relapses' probably represent acquired genetically based high-level multidrug resistance. Possibly, the addition of nonmyelosuppressive therapeutic agents such as humanized anti-CD30 monoclonal antibody or anti-CD30 immunoconjugates during the early post-transplant period may help to delay disease progression until the CC treatments can be safely started or may bypass certain chemotherapy resistance mechanisms altogether. [34] [35] [36] [37] Novel drugs such as thalidomide or bortezimib may also be worth testing in the post-transplant setting. In addition, nonmyeloablative allogeneic transplants may induce cures even among patients with highly refractory disease through a graft-versus-host disease effect and could be applied to selected patients shortly after cytoreduction with autotransplantation. 38 In summary, post-transplant CC using active agents in an alternating schedule appears to be well tolerated and associated with favorable EFS and OS rates. Therefore, post-transplant CC may be a potential strategy to reduce relapse risk after autotransplantation for advanced HD. A well-designed randomized study is needed to confirm the encouraging findings reported here. Other strategies are also urgently needed to improve the outcome in patients who are at high risk for relapse early after high-dose therapy.
